EUVIMEDEUVIMED entdecken
Crossref

Performance of the Occlutech® Atrial Flow Regulator Device in Patients With Either Failing Fontan Circulations or Irreversible Pulmonary Hypertension

Mehmet Kucuk iD, Jenny E Zablah iD, Gregory Fleming iD, Dennis Vanloozen, Oliver Aregullin, Konstantin Averin iD, Mark H Hoyer, Mark A Law, James A Kuo iD, Ryan Leahy, Christopher Iskander iD, Gareth J Morgan iD

Catheterization and Cardiovascular Interventions · 26.07.2026

DOI: 10.1002/ccd.70776 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Catheterization and Cardiovascular Interventions, online erschienen am 26.07.2026. Verfasst von Mehmet Kucuk und 11 weiteren Autor:innen. Beteiligte Einrichtung: Interventional Cardiology, Children's Hospital Colorado, Heart Institute, Aurora, Colorado, USA. Hauptthemen laut MEDLINE: Fontan Procedure, Hypertension, Pulmonary, Cardiac Catheterization, Heart Defects, Congenital. Die Arbeit nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The presence of an atrial level right to left shunt may be desirable in patients with severe pulmonary hypertension (PH) or failing Fontan circulation. The Occlutech Atrial Flow Regulator (AFR) was originally designed to create an atrial shunt for left heart failure and is currently being used off‐label in patients with PH or failing Fontan circulation. There is limited evidence supporting AFR use for these indications. Aims and Methods We performed a retrospective review of consecutive patients with Fontan circulation or severe irreversible PH who underwent AFR implantation. Comprehensive data were collected and analyzed.

Results

Sixteen Fontan and eight PH patients underwent AFR implantation. Median age and weight at implantation were 7.5 years (range 2–34) and 22.3 kg (range 11.3–80), respectively. Twenty‐eight devices were implanted in 24 patients during 27 procedures. Successful deployment was achieved in all. The device proved versatile and durable across diverse anatomic substrates, even after multiple repositioning attempts. There were no deaths or urgent surgical interventions. Transseptal puncture or Fontan baffle perforation using a Brockenbrough needle or radiofrequency before AFR implantation was required in 10 patients (42%). The most serious complication was a hemorrhagic stroke related to anticoagulation therapy. Thrombotic events occurred in three Fontan patients (11% of all implantations).

Conclusions

AFR appears to be a promising adjunctive option for PH and failing Fontan patients, with acceptable safety and clinically effective results. Device thrombosis remains a risk, particularly with smaller devices in Fontan circulation, likely related to the Fontan patients' underlying hypercoagulable state.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fontan ProcedureHypertension, PulmonaryCardiac CatheterizationHeart Defects, CongenitalPulmonary CirculationHumansRetrospective StudiesAdolescentTreatment OutcomeChildFemaleMaleChild, PreschoolProsthesis DesignAdultYoung AdultTime FactorsRisk FactorsSeverity of Illness Index

Stichwörter der Autor:innen

Atrial Flow RegulatorFontan failurecongenital heart diseaseheart failurepulmonary hypertension

Autor:innen und Institutionen

  • Interventional Cardiology, Children's Hospital Colorado, Heart Institute, Aurora, Colorado, USA.
  • Department of Pediatrics, Division of Pediatric Cardiology, Duke University Medical Center, Durham, North Carolina, USA.
  • Pediatric Cardiology, Cook Children's Medical Center, Fort Worth, Texas, USA.
  • Congenital Heart Center, Spectrum Health Helen DeVos Children's Hospital, Grand Rapids, Michigan, USA.
  • Northwell Health, Cohen Children's Medical Center, New Hyde Park, New York, USA.
  • Division of Pediatric Cardiology, Riley Hospital for Children, Indiana University, Indianapolis, Indiana, USA.

ORCID-Profile: Mehmet Kucuk, Jenny E Zablah, Gregory Fleming, Konstantin Averin, James A Kuo, Christopher Iskander, Gareth J Morgan

Zitieren

APA

Kucuk, M., Zablah, J. E., Fleming, G., Vanloozen, D., Aregullin, O., Averin, K., Hoyer, M. H., Law, M. A., Kuo, J. A., Leahy, R., Iskander, C., & Morgan, G. J. (2026). Performance of the Occlutech® Atrial Flow Regulator Device in Patients With Either Failing Fontan Circulations or Irreversible Pulmonary Hypertension. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.70776

Vancouver

Kucuk M, Zablah JE, Fleming G, Vanloozen D, Aregullin O, Averin K, et al. Performance of the Occlutech® Atrial Flow Regulator Device in Patients With Either Failing Fontan Circulations or Irreversible Pulmonary Hypertension. Catheterization and Cardiovascular Interventions. 2026. doi:10.1002/ccd.70776

BibTeX
@article{Kucuk2026,
  author = {Kucuk, Mehmet and Zablah, Jenny E and Fleming, Gregory and Vanloozen, Dennis and Aregullin, Oliver and Averin, Konstantin and Hoyer, Mark H and Law, Mark A and Kuo, James A and Leahy, Ryan and Iskander, Christopher and Morgan, Gareth J},
  title = {Performance of the Occlutech® Atrial Flow Regulator Device in Patients With Either Failing Fontan Circulations or Irreversible Pulmonary Hypertension},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2026},
  doi = {10.1002/ccd.70776}
}
Kostenlos starten →